These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 31594064)

  • 1. [Clinical characteristics of 46 pediatric diffuse large B-cell lymphoma and treatment outcome].
    Huang S; Yang J; Jin L; Duan YL; Zhang M; Zhang NN; Li Q; Zhang N; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):774-779. PubMed ID: 31594064
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
    [No Abstract]   [Full Text] [Related]  

  • 4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
    Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
    J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term efficacy and prognostic factors of Beijing Children's Hospital-2009-lymphoblastic lymphoma in the treatment of T-lymphoblastic lymphoma in children and adolescents].
    Jin L; Yang J; Duan YL; Huang S; Zhang M; Zhou CJ; Zhang NN; Zhang YH
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(29):2759-2766. PubMed ID: 39075996
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomic distribution, clinical features, and survival data of 87 cases primary gastrointestinal lymphoma.
    Ge Z; Liu Z; Hu X
    World J Surg Oncol; 2016 Mar; 14():85. PubMed ID: 26988370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical analysis of 60 children with anaplastic large cell lymphoma in a single center].
    Wang M; Mi Q; Yuan Q; Han YL; Wang JM; Luo CY; Pan C; Tang JY; Gao YJ
    Zhonghua Er Ke Za Zhi; 2021 Oct; 59(10):824-829. PubMed ID: 34587677
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.